



REVIEW

Bilingual edition English/Spanish

Optic neuropathy associated with linezolid: systematic review of cases

Neuropatía óptica asociada a linezolid: revisión sistemática de casos

David Brandariz-Núñez, Virginia Hernández-Corredoira, Eva Guarc-Prades, Bárbara García-Navarro

Pharmacy Unit, Hospital Quironsalud Barcelona, Barcelona. Spain.

Author of correspondence

David Brandariz Núñez
Plaça d'Alfonso Comín, 5-7,
08023, Barcelona. España.

Email:
vrandariz@gmail.com

Received 25 July 2018;
Accepted 25 November 2018.
DOI: 10.7399/fh.11133

How to cite this paper

Brandariz-Núñez D, Hernández-Corredoira V, Guarc-Prades E, García-Navarro B. Optic neuropathy associated with linezolid: systematic review of cases. *Farm Hosp.* 2019;43(2):61-65.

Abstract

Objective: Collect and analyze all the described cases of optic neuropathy associated with linezolid.

Method: A systematic review of cases was carried out through a search in PubMed-Medline, Embase and ScienceDirect, between September 2002 and April 2018. The demographic, clinical and ophthalmology characteristics of each patient were evaluated.

Results: A total of 33 cases from 26 independent articles were analyzed. The mean age was 44.97 ± 21.40 years (range: 6-79) and 16 (50%) of 32 cases were women. The duration of treatment with linezolid until onset of symptoms was greater than 28 days in 29 (90.6%) of 32 documented cases. The mean time of exposure to onset of symptoms was 8.5 ± 8.6 months (range: 0.33-50). A total of 12 of 26 adult patients received linezolid 600 mg/24 h, starting. In 30 (90.9%) patients loss of visual acuity was documented. Linezolid was withdrawn in all cases once the diagnosis was confirmed, with clinical improvement in 31 (93.9%) cases.

Conclusions: Optic neuropathy is a reversible complication related to the prolonged use of linezolid and regardless of the dose. We recommend follow-up in patients with long treatments (> 28 days) and ophthalmological exploration in those with visual alterations for the early diagnosis of neuropathy and early withdrawal of linezolid.

Resumen

Objetivo: Recoger y analizar todos los casos descritos de neuropatía óptica asociada a linezolid.

Método: Se realizó una revisión sistemática de casos mediante una búsqueda en PubMed-Medline, Embase y ScienceDirect, entre septiembre de 2002 y abril de 2018. Se evaluaron las características demográficas, clínicas y oftalmológicas de cada paciente.

Resultados: Se analizaron un total de 33 casos procedentes de 26 artículos independientes. La media de edad fue de $44,97 \pm 21,40$ años (rango: 6-79) y 16 (50%) de los 32 casos fueron mujeres. La duración del tratamiento con linezolid hasta el comienzo de los síntomas fue superior a 28 días en 29 (90,6%) de los 32 casos documentados. El tiempo medio de exposición hasta el comienzo de los síntomas fue de $8,5 \pm 8,6$ meses (rango: 0,33-50). Un total de 12 de 26 pacientes adultos recibieron linezolid 600 mg/24 h de inicio. En 30 (90,9%) pacientes se documentó pérdida de la agudeza visual. Se retiró linezolid en todos los casos una vez confirmado el diagnóstico, con mejoría clínica en 31 (93,9%) casos.

Conclusiones: la neuropatía óptica es una complicación reversible relacionada con el uso prolongado de linezolid e independiente de la dosis. Recomendamos realizar un seguimiento a los pacientes con tratamientos largos (> 28 días) y exploración oftalmológica en aquellos con alteraciones visuales para el diagnóstico temprano de la neuropatía y la retirada precoz de linezolid.

KEYWORDS

Linezolid; Multidrug resistant tuberculosis; Optic neuropathy; Oxazolidinones; Side effects.

PALABRAS CLAVE

Efectos adversos; Linezolid; Neuropatía óptica; Oxazolidinonas; Tuberculosis multirresistente.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<http://creativecommons.org/licenses/by-nc-sa/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

Introduction

Linezolid is a synthetic antibiotic within the oxazolidinone class, with activity against gram positive bacteria and mycobacteria. Its antibacterial spectrum includes methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin-resistant *Staphylococcus epidermidis* (MRSE) and vancomycin-resistant *Enterococcus*¹. It is approved for use in nosocomial pneumonia, community-acquired pneumonia and skin and soft tissue infection (SSTI), and it has demonstrated efficacy in the treatment of osteoarticular and prosthetic materials infections². On the other hand, according to the classification by the World Health Organization, it belongs to Group 5 of anti-tuberculosis agents used as 2nd line in multi-drug resistant tuberculosis, caused by multi-drug resistant *Mycobacterium tuberculosis* (MDR-TB) and extensively-drug resistant *Mycobacterium tuberculosis* (XDR-TB)³.

Linezolid is an antibiotic with a good safety profile, though adverse effects have been described, such as: diarrhea, vomiting, headache, anaemia, thrombocytopenia, lactic acidosis, and peripheral and optic neuropathy. In clinical practice, it has been used for complicated infections requiring prolonged treatment. However, its safety in >28-day treatments has not been systematically evaluated in controlled clinical trials. Overall, optic and peripheral neuropathies are side effects observed in prolonged treatments. Optic neuropathy is defined as a clinical syndrome characterized by blurry vision, loss of visual acuity, damage in the papillomacular bundle, presence of central or ketocentral scotoma in the range of vision, and alteration of colors⁴.

Linezolid acts by inhibiting the synthesis of bacterial proteins through the specific binding of the ribosomal sub-unit 50S. This blockade has almost no impact on mammal proteins, but with prolonged treatments it can interfere in the protein synthesis of mitochondria, causing its dysfunction⁵. The alteration of the mitochondrial oxidative metabolism in the optic nerve is the hypothesis supporting the etiology of optic neuropathy by linezolid.

Some of the outstanding causes that can originate optic neuropathy are: chemotherapy agents such as ethambutol, isoniazid, phosphodiesterase inhibitors, anti-tumor necrosis factor agents (anti-TNFs), toxic agents such as methanol and mercury, alcoholism and smoking, as well as nutritional deficiencies, such as lack of vitamin B12, thiamine, and folic acid⁶.

There are limited data on the frequency of optic neuropathy associated with linezolid. Cohort studies and case series described a relatively low prevalence, ranging between 1.3% and 3.3%^{7,9}. However, in a meta-analysis conducted in 2012, it was observed that there was a 13.2% increase in prevalence¹⁰; and most recently, in 2015, an 8%¹¹.

The objective of the present review was to collect all described cases of optic neuropathy associated with linezolid that had been published in literature, and to analyze the demographical, clinical and ophthalmological characteristics of this group of patients.

Methods

A qualitative systematic review was conducted on cases of optic neuropathy associated with linezolid, following the guidelines established by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The analysis included patients from case reports or series of cases from original articles. The search was conducted using the following databases: PubMed-Medline, Embase and ScienceDirect, between September, 2002 and April, 2018. The terms of search were "linezolid" and "optic neuropathy", conducted for "All field". The search equation for Medline was: (linezolid[MeSH Terms]) AND optic neuropathy[MeSH Terms]. Titles and abstracts of the articles were used for the process of selection; articles in Spanish, English, French and German were analyzed. Figure 1 shows the flow diagram for case selection.

Demographical and clinical characteristics of each patient were collected and analyzed: age, gender, background, concomitant treatment, type of infection and bacteria involved, daily dose of linezolid and total accumulated dose, time of exposure to linezolid until the onset of symptoms and time of exposure until withdrawal, treatment for optic neuropathy and its efficacy, presence of other adverse effects attributed to linezolid, and time of follow-up since antibiotic withdrawal. Clinical ophthalmological characteristics were also collected and analyzed: presence of blurry vision, type of ocular alteration: bilateral or unilateral, presence of color alteration, visual acuity (VA), type of alteration in ocular fundus and in the range of vision.

Descriptive analysis was conducted through the SPSS program (version 20.0). Qualitative variables were expressed in percentages, and quantitative variables in mean value (\pm standard deviation).

Results

According to the search criteria, 59 studies were obtained in total. During the selection process, 33 articles were excluded, and the analysis included 33 cases in total of optic neuropathy associated with linezolid, from 26 independent articles (Figure 1).

Table 1 shows the clinical and demographical characteristics of these 33 cases: 16 out of 32 (50%) patients were female, and two were pediatric patients. Their mean age was 44.97 ± 21.40 years (range: 6-79). The duration of treatment with linezolid until the onset of symptoms was >28 days, in 29 (90.6%) out of 32 documented cases. The mean time of exposure until the onset of symptoms and the mean time of exposure until withdrawal of linezolid was 8.5 ± 8.6 months (range: 0.33-50) and 10.1 ± 10.3 months (range: 0.53-56) respectively. The mean time of follow-up was 5.6 ± 5.0 months (range: 1-23). Fourteen (14) patients received linezolid ≤ 600 mg/24 h (including the two pediatric patients), eight received 600 mg/12 h and two initiated treatment at 600 mg/12 h and then were adjusted to 600 mg/24 h. In the rest of cases, the dose used was not available. The mean dose accumulated was 201.6 ± 222.9 g (range: 18-1,230).




Figure 1. Flow diagram for selection of references.

Table 1. Demographical and clinical characteristics of the 33 cases of optic neuropathy associated with linezolid

Case/ Reference	Age/ Gender	Type of infection/Bacteria	Time of exposure until symptoms/Time of exposure until withdrawal (m)	Linezolid dose (mg)	Linezolid accumulated dose (g)
1/12	71/F	Prosthesis infection/MRSA	10.00/10.50	-	-
2/12	45/M	Prosthesis infection. Vertebral/MRSA	10.00/11.00	-	-
3/13	72/F	Prosthesis infection/MRSE	10.25/11.00	-	-
4/14	75/F	Pneumonia/ <i>Mycobacterium abscesus</i>	11.00/16.00	600/24 h	288.0
5/14	73/F	Pneumonia/MAI	8.00/11.00	600/24 h	198.0
6/15	27/F	Osteomyelitis/MRSA	5.13/6.40	-	139.5
7/16	56/M	Osteomyelitis/MRSA	50.00/56.00	600/12 h →600/24*	1,230.0
8/17	28/F	Pneumonia/MRSA	0.53/0.53	600/12 h	19.5
9/5	6/M	Osteomyelitis (mastoiditis)/MRSA	12.00/-	340	124.1
10/18	70/F	Osteomyelitis/MRSA	-	600/12 h →600/24*	-
11/19	45/M	Tuberculosis/TB-XDR	6.00/7.00	600/24 h	126.0
12/20	19/M	Tuberculosis/TB-MDR	0.33/1.00	600/24 h	18.0
13/20	40/F	Tuberculosis/TB-MDR	7.00/9.00	600/24 h	162.0
14/20	48/F	Tuberculosis/TB-MDR	6.00/7.00	600/24 h	126.0
15/21	30/M	Tuberculosis/TB-MDR	9.00/-	600/24 h	162.0
16/22	22/M	Tuberculous meningitis/TB-MDR	1.00/-	600/24 h	18.0
17/23	61/M	Tuberculosis/TB-MDR	6.00/-	-	-
18/24	49/F	Septic hip arthritis/MRSA	7.00/7.50	-	-
19/25	68/M	Tuberculosis/ <i>Mycobacterium bovis</i>	5.00/6.00	600/12 h	216.0
20/26	41/F	Tuberculosis/TB-MDR	17.00/20.00	-	-
21/27	43/F	Spread lymph-node tuberculosis/ TB-MDR	3.00/-	-	-
22/28	28/M	Tuberculosis/TB-MDR	9.00/-	600/24 h	162.0
23/29	29/F	Pneumonia/Vancomycin-resistant <i>Enterococcus</i>	0.53/0.53	600/12 h	19.5
24/30	15/M	IL-12RB1 deficiency/ <i>Mycobacterium bovis</i>	8.00/-	-	-
25/31	40/F	Wound infection, frontal lobe abscess/MRSA	6.00/6.50	600/12 h	234.0
26/31	66/M	Defibrillator infection, bacteremia/ MRSA	5.00/5.00	600/12 h	180.0
27/31	79/F	Wound infection/MRSA	10.00/10.00	600/12 h	360.0
28/32	63/F	Prosthesis infection/MRSA	4.00/4.00	600/12 h	144.0
29/33	76/-	Prosthesis infection/MRSA	6.00/6.00	600/12 h	216.0
30/34	32/M	Tuberculosis/TB-XDR	10.00/10.25	600/24 h	184.5
31/34	26/M	Tuberculosis/TB-XDR	5.00/5.33	600/24 h	96.0
32/35	7/M	Lymph-node tuberculosis/ <i>Mycobacterium nonchomogenicum</i>	6.00/7.00	10 mg/kg/12 h	-
33/36	34/M	Tuberculosis/TB-MDR	18.00/19.00	600/24 h	342.0

F: female; M: male; m=months; MAI: *Mycobacterium avium intracelulare*; MRSA: methicillin-resistant *Staphylococcus aureus*; MRSE: methicillin-resistant *Staphylococcus epidermidis*; TB-MDR: multi-drug resistant *Mycobacterium tuberculosis*; TB-XDR: extensively drug-resistant *Mycobacterium tuberculosis*.

*Treatment initiation at 1,200 mg/24 h and dose reduction at 600 mg/24 h.

In 30 of the 33 (90.9%) patients, VA loss was observed; 28 (93.3%) of the 30 documented cases presented bilateral VA alteration, and two presented unilateral VA alteration. 19 (82.7%) of the 23 documented cases suffered color alteration. In terms of ocular fundus examination, optic disc alterations were detected in 23 (79.3%) of the 29 cases documented. In the range of vision examination, defects were collected in 22 (95.7%) of the 23 patients documented, including: seven central scotomas, seven ketocentral scotomas, two with peripheral constrictions, and one with generalized field involvement.

Linezolid was withdrawn in all cases, once diagnosis had been confirmed, and clinical improvement was observed in 31 of the 33 (93.9%) patients. In one case there was symptom worsening, and another patient presented total and irreversible loss of vision, regardless of linezolid discontinuation. In one patient, linezolid was re-initiated with a subsequent final withdrawal, due to a rapid relapse of symptomatology.

In five patients, treatment with corticosteroids was initiated; three of them received systemic corticosteroids, one received ophthalmic topical corticosteroids, and one received both. Clinical improvement was observed in two patients with the administration of corticosteroids, once linezolid had been withdrawn, while no satisfactory clinical response was reached in the other three, but there was a worsening in neuropathy before linezolid withdrawal, and one patient even presented total and irreversible vision loss, as already mentioned.

In 17 (48.5%) cases, symptoms compatible with peripheral neuropathy were observed, while only five (14.3%) were confirmed through electrodiagnosis. Only four of 13 (30.8%) cases presented symptom recovery, one of them partial and the other slow and progressive.

Two patients suffered lactic acid elevation, and one of them presented also hepatic encephalopathy, myopathy and renal impairment. In one case, myelosuppression secondary to linezolid was described (anaemia and neutropenia).

Regarding nutritional status, one case presented vitamin B12 deficiency associated with chronic gastritis, and another one had a mild deficiency of folic acid.

On the other hand, three cases received concomitant treatment with ethambutol, two with capreomycin, seven with quinolones, two with isoniazid, and one received previous treatment with vincristine.

Discussion

The increase in the incidence of multi-drug resistant tuberculosis in the past two decades has represented a setback for the control of the tuberculosis epidemics at world level, and forced to use second-line anti-tuberculosis drugs, such as linezolid. Treatment duration has led to an increase in adverse effects associated with prolonged exposure, such as optic neuropathy. In our review, we have collected and analyzed 33 cases in total of optic neuropathy associated with linezolid; their main infections were caused by multi-drug resistant TB, among others.

Optic neuropathy secondary to linezolid is associated with its prolonged use. In the meta-analysis by Zhang *et al.*, with 23 optic and 79 peripheral neuropathies, the duration of treatment with linezolid was >5 months¹¹. In other study on a retrospective cohort with five optic neuropathy cases, the time of linezolid administration was >7 months in all cases, and the mean time of administration was 10 months³⁷. According to the results mentioned, in our study the mean treatment duration was 10 months. On the other hand, it is worth highlighting the presence of three cases of optic neuropathy associated with short treatments <28 days^{17,20,29}.

Bibliography

1. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. *Clin Pharmacokinet.* 2003;42:1129-40.
2. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. *Diagn Microbiol Infect Dis.* 2007;59:173-9.
3. Schechter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. *Clin Infect Dis.* 2010;50:49-55.
4. Glaser JS. Nutritional and toxic optic neuropathies. In: Glaser JS, ed. *Neuro-Ophthalmology*. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 1999. p. 181-6.

The dose ≤ 600 mg/24 h vs. ≥ 600 mg/24 h, in the meta-analysis by Sotgiu *et al.*, reduced the frequency of optic neuropathy and other adverse effects, without compromising efficacy in patients with multi-drug resistant tuberculosis⁹. Subsequently, in the previously discussed meta-analysis by Zhang, the dosing ≤ 600 mg/24 h did not show a reduction in optic neuropathy in this type of patients¹¹. In our study, we found up to 12 cases of adult patients with a 600 mg/24 h initial dose, who experienced optic neuropathy regardless of the reduced dose, which shows the need for ophthalmological follow-up and monitoring for all patients with prolonged treatments, regardless of the dose used.

Optic neuropathy associated with linezolid is a reversible process in most cases, and there is symptom improvement once the antibiotic has been withdrawn. In our review, only one case suffered worsening regardless of linezolid withdrawal²⁰, and another case suffered a total loss of vision¹⁷. On the other hand, peripheral neuropathy is usually an irreversible process, where no clinical benefit is observed regardless of antibiotic withdrawal³⁸. Only four cases compatible with peripheral neuropathy experienced improvement in our study^{21,25,28,30}.

The efficacy of corticosteroid treatment is a controversial matter. In their study, Mehta *et al.* observed clinical improvement, both in patients treated with corticosteroids and in those not treated³⁷. In our review, corticosteroid administration was beneficial in two cases^{12,13}, while three experienced a worsening in their neuropathy^{15,17,35}. Therefore, more studies are necessary, on a wider population, in order to reach final conclusions about the benefit of corticosteroids.

Finally, it is worth highlighting the low incidence of myelotoxicity (anemia and thrombocytopenia) associated with linezolid in our series, with only one patient documented. This can be explained by a difference in mechanism, regarding mitochondrial inhibition in optic neuropathy.

Our review presents some limitations. Firstly, there is a small sample size, and we have evaluated cases from articles with potential publication bias. Secondly, the level of detail provided in each case was not homogeneous and, therefore, was subject to a certain level of data interpretation. Regardless of limitations, we believe that this review will provide useful information.

In conclusion, optic neuropathy is a complication associated with the prolonged use of linezolid, regardless of the dose received, and reversible in most cases. The increasing use of linezolid in regimens for treatment of multi-drug resistant tuberculosis and complicated infections caused by resistant gram positive bacteria, has led to an increase in the incidence of optic neuropathy associated with the prolonged use of linezolid. Therefore, it is important to conduct multidisciplinary follow-up for patients on long treatment regimens > 28 days, particularly in those with visual alterations. It would be convenient to conduct an exhaustive ophthalmological examination (to evaluate visual acuity, range of vision, color vision, and ocular fundus) in order to be able to conduct an early diagnosis of optic neuropathy, and therefore an early withdrawal of linezolid.

Funding

No funding.

Conflict of interests

No conflict of interests.

9. Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V, Meintjes G, *et al*. Linezolid for multidrug-resistant tuberculosis in HIV-infected and uninfected patients. *Eur Respir J*. 2015;46(1):271-4.
10. Satgiu G, Centis R, D'Ambrosio L, Alffenaar JWC, Anger HA, Caminero JA, *et al*. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. *Eur Respir J*. 2012;40(6):1430-42.
11. Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, *et al*. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. *J Thorac Dis*. 2015;7(4):603-15.
12. Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F, *et al*. Linezolid-associated toxic optic neuropathy: a report of 2 cases. *Clin Infect Dis*. 2003;37:1389-91.
13. Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. *J Antimicrob Chemother*. 2004;53(6):1114-5.
14. McKinley S, Foroosan R. Optic Neuropathy Associated with Linezolid Treatment. *J Neuroophthalmol*. 2005;25:18-21.
15. Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. *Am J Ophthalmol*. 2005;139(6):1114-6.
16. Kulkarni K, Del Priore LV. Linezolid induced toxic optic neuropathy. *Br J Ophthalmol*. 2005;89(12):1664-5.
17. Azamfirei L, Copotoiu SM, Branzaniuc K, Szederjesi J, Copotoiu R, Berteanu C. Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy. *Pharmacoepidemiol Drug Saf*. 2007 [accessed 5/3/2018];16(4):402-4. Available at: <http://dx.doi.org/10.1002/pds.1320>
18. Kiuchi K, Miyashiro M, Kitagawa C, Wada S. Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis. *Jpn J Ophthalmol*. 2009;53(4):420-4.
19. Karuppannasamy D, Raghuram A, Sundar D. Linezolid-induced optic neuropathy. *Indian J Ophthalmol*. 2014;62:497-500.
20. Khadilkar SV, Yadav RS, Rajan S. Linezolid Optic Neuropathy: Be Careful and Quick. *J Assoc Physicians India*. 2013;61(11):866-7.
21. Chaitali P, Suresh R. Comment on linezolid induced optic neuropathy. *Indian J Ophthalmol*. 2015;63:75-6.
22. Agrawal R, Addison P, Saihan Z, Pefkianaki M, Pavesio C. Optic neuropathy secondary to linezolid for multidrug-resistant mycobacterial spinal tuberculosis. *Ocul Immunol Inflamm*. 2015;23(1):90-2.
23. Park DH, Park TK, Ohn YH, Park JS, Chang JH. Linezolid induced retinopathy. *Doc Ophthalmol*. 2015;131(3):237-44.
24. Ishii N, Kinouchi R, Inoue M, Yoshida A. Linezolid-induced optic neuropathy with a rare pathological change in the inner retina. *Int Ophthalmol*. 2016;36(6):761-6.
25. Hernández Prats C, Linares Tello F, Climent Grana E, Fernández Aracil C. Peripheral and optic neuropathy associated to linezolid in multidrug resistant *Mycobacterium bovis* infection. *Med Clin (Barc)*. 2005;124:797-8.
26. Han J, Lee K, Rhiu S, Lee JB, Han SH. Linezolid-associated optic neuropathy in a patient with drug-resistant tuberculosis. *J Neuroophthalmol*. 2013;33:316-8.
27. Eisenack J, Landau K, Wildberger H, Knecht P. Linezolid-associated optic neuropathy. *Klin Monbl Augenheilkd*. 2012;229:433-4.
28. Xerri O, Lemaire B, Nasser G, Rousseau-Huvev B, Labetoulle M, Rousseau A. Neuropathie optique toxique grave liée au linézolide. *J Fr Ophtalmol*. 2015;38(3):55-8.
29. Joshi L, Taylor SRJ, Large O, Yacoub S, Lightman S. A Case of Optic Neuropathy after Short-Term Linezolid Use in a Patient with Acute Lymphocytic Leukemia. *Clin Infect Dis [Internet]*. 2009 [accessed 5/3/2018];48(7):73-4. Available at: <https://academic.oup.com/cid/article-lookup/doi/10.1086/597298>
30. Rosenzweig SD, Yancoski J, Bernasconi A, Krasovec S, Marciano BE, Casimir L, *et al*. Thirteen years of culture-positive *M. bovis*-BCG infection in an IL-12Rβ1 deficient patient: Treatment and outcome. *J Infect*. 2006;52(3):10-3.
31. Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid associated toxic optic neuropathy. *Neurology*. 2006;66:595-8.
32. De Vriese A, Coster R, Smet J, Seneca S, Lowering A, Van Haute LL *et al*. Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. *Clin Infect Dis*. 2006;42:1111-7.
33. Corallo C, Paull A. Linezolid-induced neuropathy. *Med J Aust*. 2002;177:332.
34. Srivastava A, Kshetrimayum S, Gupta SK, Kant S. Linezolid-induced optic neuropathy in XDR pulmonary TB: A case series. *Indian J Tuberc [Internet]*. 2017 [accessed 5/3/2018];64(2):129-33. Available at: <http://dx.doi.org/10.1016/j.ijtb.2016.11.010>
35. González Saldaña N, Galvis Trujillo DM, Borbolla Pertierra AM, Mondragón Pineda AI, Juárez Olguín H. Linezolid-associated optic neuropathy in a pediatric patient with *Mycobacterium nonchromogenicum*: A case report. *Medicine (Baltimore)*. 2017 Dec;96(50):e9200.
36. Kreps EO, Brown L, Rennie IG. Clinical recovery in linezolid-induced optic nerve toxicity. *Acta Ophthalmol*. 2017;95(4):341-2.
37. Mehta S, Das M, Laxmeshwar C, Jonckheere S, Thi SS, Isaakidis P. Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India. *PLoS One [Internet]*. 2016 [accessed 5/3/2018];11(9):1-12. Available at: <http://dx.doi.org/10.1371/journal.pone.0162138>
38. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. *Lancet Infect Dis*. 2004;4(8):528-31.